Table 1.

MAGE-D4 expression and immunogenicity with clinicopathological characteristics in glioma

Case no.	Histology	Age	Sexa	IHCb	ELISAc
WHO grade IV
1	Glioblastoma	59	M	+	+
2	Glioblastoma	36	F	+++	-
3	Glioblastoma	60	F	+++	-
4	Glioblastoma	48	F	-	-
WHO grade III
5	Anaplastic astrocytoma	43	M	++	-
6	Anaplastic astrocytoma	37	M	+++	-
7	Anaplastic astrocytoma	53	F	++	-
8	Anaplastic astrocytoma	31	M	++	-
9	Anaplastic astrocytoma	52	M	-	-
10	Anaplastic ependymoma	52	M	++	+
WHO grade II
11	Diffuse astrocytoma	11	F	++	+
12	Diffuse astrocytoma	24	F	++	+
13	Diffuse astrocytoma	54	M	+	+
14	Diffuse astrocytoma	52	F	++	-
15	Diffuse astrocytoma	18	F	+++	-
16	Diffuse astrocytoma	34	F	++	-
17	Diffuse astrocytoma	30	M	-	-
18	Diffuse astrocytoma	52	F	-	-
19	Diffuse astrocytoma	52	M	-	-
20	Diffuse astrocytoma	53	F	++	-
21	Diffuse astrocytoma	30	M	+++	-
22	Diffuse astrocytoma	58	M	+	-
23	Diffuse astrocytoma	53	M	-	-
24	Ependymoma	16	F	++	-
WHO grade I
25	Pilocytic astrocytoma	44	M	++	+
26	Pilocytic astrocytoma	3	F	++	-
27	Pilocytic astrocytoma	16	F	+++	-

^aM, male; F, female.

^bMAGE-D4 protein expression was judged according to the staining intensity and the percentage of positive cells: -, negative; +, weak expression; ++, moderate expression; +++, strong expression.

^cThe seroreactivities of MAGE-D4 are described as -, negative; +, positive.